Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nu-3 Gel in Infected Diabetic Foot Ulcers
NCT07565506Phase 2Recruiting
- Sponsor
- Lakewood-Amedex Biotherapeutics
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bisphosphocin nu-3 in diabetic foot ulcer (DFU), sponsored by Lakewood-Amedex Biotherapeutics. Started Aug 2026; status: recruiting.
02
Drugs
bisphosphocin nu-3
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT07565506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565506.